What question did this study set out to answer?

This research examines cyclin-dependent kinases as therapeutic targets for cancer treatment. It aims to highlight recent advancements and challenges in CDK inhibitor therapies.

March 10, 2026International Journal of Cancer

Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities

View Full Paper

Ask AI

Bookmark

Authors

NJNing JuShandong Normal University LZLi ZhaoShandong Normal University SYShanshan YinShandong Normal University

Discussion

Member takes

Implication

Review demonstrates recent advances in CDK inhibitors for cancer, suggesting new treatment opportunities.

Key Points

This research examines cyclin-dependent kinases as therapeutic targets for cancer treatment. It aims to highlight recent advancements and challenges in CDK inhibitor therapies.
Review of literature on cyclin-dependent kinases in cancer.
Summarization of clinical outcomes related to CDK4/6 inhibitors.
Assessment of dual CDK4/6 and CDK2 inhibition effects.
Evaluation of CDK inhibitors in conjunction with cancer immunotherapy.
CDK4/6 inhibitors have shown clinical efficacy in HR+/HER2- metastatic breast cancer.
Selective CDK2 inhibitors have demonstrated promising antitumor activity.
Dual inhibition enhances effectiveness against CDK4/6 resistance.
CDK inhibitors can induce cellular senescence and improve immunotherapy outcomes.

Cite This Study

Ju et al. (2026) studied this question.

synapsesocial.com/papers/69af950a70916d39fea4c3b1 https://doi.org/10.1002/ijc.70442

View Full Paper

Ask AI

Bookmark

Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities

Discussion

Member takes

Implication

Key Points

Cite This Study

Cyclin‐dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider